Whole Woman’s Health Alliance v. FDA
Case filed on behalf of abortion providers in three states challenges FDA restrictions on mifepristone.
Case filed on behalf of abortion providers in three states challenges FDA restrictions on mifepristone.
Case to be argued at the Fifth Circuit Court of Appeals on May 17.
New state rule would have effectively eliminated access to abortion care for most Montanans insured through Medicaid.
This brief was filed on behalf of over 200 reproductive health, rights, and justice organizations, including the Center for Reproductive Rights. These organizations have directly seen the importance of medication abortion to individuals’ health and bodily autonomy, as well as mifepristone’s efficacy and safety as a tool for achieving those goals; have a unique window […]
This brief was filed on behalf of Public Citizen, a non-profit consumer advocacy organization with members in all fifty states which, among other things, works to advance access to health care and to ensure strong protections for public health. The brief emphasizes that the FDA engages in rigorous and ongoing expert study of detailed scientific […]
This brief was filed on behalf of 24 states who have an important interest in protecting the health, safety, and rights of its residents, including an interest in ensuring safe access to essential reproductive health care. The brief emphasizes medication abortion is a safe and effective method for terminating pregnancies and is indispensable to reproductive […]
This brief was filed on behalf of Physicians for Reproductive Health, a doctor-led nonprofit that seeks to assure meaningful access to comprehensive reproductive health services, including contraception and abortion, as part of mainstream medical care and has insight into the challenges providers and patients face when confronted by actions designed or applied to prevent pregnant […]
This brief was filed on behalf of dozens of pharmaceutical companies, pharmaceutical company executives, and industry investors from across the United States. The brief emphasizes that Congress intended the FDA, not courts, to serve as the expert arbiter of drug safety and effectiveness and the FDA’s drug approval process is the gold standard of review. […]
This brief was filed on behalf of the Pharmaceutical Research and Manufacturers of America (PhRMA), Advanced Medical Technology Association (AdvaMed), Consumer Healthcare Products Association (CHPA), and National Association of Manufacturers (NAM) for their shared interest in protecting against disruptions to the stable and predictable statutory framework Congress created to govern drug approvals by the FDA. […]
This brief was filed on behalf of Leukemia & Lymphoma Society and 19 other additional patient and provider advocacy organizations listed in the Appendix, which represent millions of patients across the United States who have serious health conditions and depend on drugs approved by the Food and Drug Administration (“FDA”) for treatment. The brief emphasizes […]